aspartate aminotransferase, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, aspartate aminotransferase

Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ 2008 Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47: 949-957. *
Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD 2001 Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96: 2711-2717. *
Adams LA, Zein CO, Angulo P, Lindor KD 2004 A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368. *
Agarwal K, Czaja AJ, Donaldson PT 2007 A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens 69: 227-235. *
Agarwal K, Czaja AJ, Jones DE, Donaldson PT 2000 Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 31: 49-53. *
Ai Y, Liu SY, Yao Q 2004 Clinical characteristics of 1241 cases of intrahepatic cholestasis of pregnancy. Zhonghua Fu Chan Ke Za Zhi 39: 217-220.
Ajamieh HH, Menendez S, Martinez-Sanchez G, Candelario-Jalil E, Re L, Giuliani A, Fernandez OS 2004 Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion. Liver Int. 24: 55-62. *
Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA 2008 Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment. Pharmacol. Ther. 28: 209-220. *
Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A 2006 Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med. J. 47: 147-151. *
Alarcon-Corredor OM, Alfonso R 2007 Clinical and biochemical alterations in rats treated with high doses of vitamin A. Arch. Latinoam. Nutr. 57: 224-230.
Aldemir M, Faruk Gey I K M, Faruk Kokoglu O, Buyukbayram HI, Hosoglu SI, Yagmur Y 2003 Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats. ANZ J. Surg. 73: 722-726. *
Aleryani SL, Cluette-Brown JE, Khan ZA, Hasaba H, Lopez de Heredia L, Laposata M 2005 Fatty acid methyl esters are detectable in the plasma and their presence correlates with liver dysfunction. Clin. Chim. Acta 359: 141-149. *
Alipour M, Omri A, Smith MG, Suntres ZE 2007 Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries. J. Endotoxin Res. 13: 297-304.
Allam G 2007 Vasoactive intestinal peptide inhibits liver pathology in acute murine schistosomiasis mansoni and modulates IL-10, IL-12 and TNF-alpha production. Immunobiology 212: 603-612.
Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M 2008 A critical role for matrix metalloproteinases in liver regeneration. J. Surg. Res. 145: 192-198. *
American Gastroenterological Association 2002 American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123: 1364-1366. *
Anderson CD, Pierce J, Nicoud I, Belous A, Knox CD, Chari RS 2005 Modulation of mitochondrial calcium management attenuates hepatic warm ischemia-reperfusion injury. Liver Transpl. 11: 663-668. *
Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A 2003 Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J. Clin. Virol. 27: 59-68.
Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, Anderson ML, Mahoney DW, Lindor KD 1999 Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J. Hepatol. 30: 830-835. *
Angulo P, Jorgensen RA, Kowdley KV, Lindor KD 2008 Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig. Dis. Sci. 53: 1716-1720. *
Angulo P, Keach JC, Batts KP, Lindor KD 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362. *
Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD 2000 Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32: 897-900. *
Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S 2005 Protective effect of resveratrol against oxidative stress in cholestasis. J. Surg. Res. 127: 112-117. *
Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, Moriyama M, Iwasaki A, Sugitani M, Arakawa Y 2004 PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J. Gastroenterol. 39: 490-495. *
Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S 2007 Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410. *
Bahcecioglu IH, Koca SS, Poyrazoglu OK, Yalniz M, Ozercan IH, Ustundag B, Sahin K, Dagli AF, Isik A 2008 Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation 31: 215-221.
Balaji Raghavendra Rao H, Sathivel A, Devaki T 2004 Antihepatotoxic nature of Ulva reticulata (Chlorophyceae) on acetaminophen-induced hepatoxicity in experimental rats. J. Med. Food. 7: 495-497.
Balderas-Renteria I, Camacho-Corona Mdel R, Carranza-Rosales P, Lozano-Garza HG, Castillo-Nava D, Alvarez-Mendoza FJ, Tamez-Cantu EM 2007 Hepatoprotective effect of Leucophyllum frutescens on Wistar albino rats intoxicated with carbon tetrachloride. Ann. Hepatol. 6: 251-254. *
Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N 2001 Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest. Endosc. 53: 308-312. *
Barton CC, Ganey PE, Roth RA 2000 Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol. Sci. 58: 208-215. *
Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA 2000 Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol. Sci. 55: 444-452. *
Battochio AP, Coelho KL, Sartori MS, Coelho CA 2008 Hepatoprotective effect of water soluble extract of Coleus barbatus on cholestasis on young rats. Acta Cir. Bras. 23: 220-229. *
Beau P, Labat-Labourdette J, Ingrand P, Beauchant M 1994 Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J. Hepatol. 20: 240-244.
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307. *
Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M, et al 1993 Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J. Hepatol. 19: 459-464.
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *
Bernatsky S, Ramsey-Goldman R, Lachance S, Pineau CA, Clarke AE 2006 Lymphoma in a patient with systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 570-574. *
Bessems M, Doorschodt BM, van Vliet AK, van Gulik TM 2005 Improved rat liver preservation by hypothermic continuous machine perfusion using polysol, a new, enriched preservation solution. Liver Transpl. 11: 539-546. *
Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD 2000 A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2338-2342. *
Bhatia AL, Sharma A, Patni S, Sharma AL 2007 Prophylactic effect of flaxseed oil against radiation-induced hepatotoxicity in mice. Phytother. Res. 21: 852-859. *
Bjornsson E, Nordlinder H, Olsson R 2006 Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44: 791-797. *
Bjornsson E, Olsson R 2005 Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42: 481-489. *
Blaszyk H, Wild PJ, Oliveira A, Kelly DG, Burgart LJ 2005 Hepatic copper in patients receiving long-term total parenteral nutrition. J. Clin. Gastroenterol. 39: 318-320.
Borini P, Guimaraes RC 2003 Noninvasive classification of liver disease in asymptomatic and oligosymptomatic male alcoholics. Braz. J. Med. Biol. Res. 36: 1367-1373. *
Brockmann JG, August C, Wolters HH, Homme R, Palmes D, Baba H, Spiegel HU, Dietl KH 2005 Sequence of reperfusion influences ischemia/reperfusion injury and primary graft function following porcine liver transplantation. Liver Transpl. 11: 1214-1222. *
Bruguera M, Barrera J, Corradi F, Mas A 2005 Hypertransaminasemia greater than 400 U/l in adults attended. Gastroenterol. Hepatol. 28: 15-19.
Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR 2004 Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum. Pathol. 35: 1070-1082.
Bueno MR, Daneri A, Armendariz-Borunda J 2000 Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 33: 915-925. *
Cadle RM, Mansouri MD, Darouiche RO 2006 Vancomycin-induced elevation of liver enzyme levels. Ann. Pharmacother. 40: 1186-1189.
Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M 2007 Adult-onset Still's disease. Int. J. Clin. Pract. May 18 [Epub ahead of print].
Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F 2005 A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42: 1373-1381. *
Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, LaRusso NF 1989 Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96: 790-794.
Carr DF, Alfirevic A, Tugwood JD, Barratt BJ, Sherwood J, Smith J, Pirmohamed M, Kevin Park B 2007 Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics 17: 961-972.
Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP 2004 Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr. Transplant. 8: 362-366.
Chalasani N, Saha C, Teal E 2007 Are there ethnicity-based differences in the evaluation of individuals with abnormal liver biochemistries? J. Hepatol. 47: 123-127. *
Chalasani N, Teal E, Hall SD 2005 Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am. J. Gastroenterol. 100: 1317-1321. *
Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD 2007 Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226. *
Chen HW, Chen HL, Ni YH, Lee NC, Chien YH, Hwu WL, Huang YT, Chiu PC, Chang MH 2008 Chubby face and the biochemical parameters for the early diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency. J. Pediatr. Gastroenterol. Nutr. 47: 187-192.
Chen W, Gluud C 2003 Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626. *
Chen YC, Huang LT, Wang SM, Tiao MM, Liu JW 2007 Acute hepatitis A infection in children: a 20-year experience of a medical center in Southern Taiwan. Acta Paediatr. Taiwan 48: 131-134.
Cheng F, Li Y, Feng L, Li S 2008 Effects of tetrandrine on ischemia/reperfusion injury in mouse liver. Transplant. Proc. 40: 2163-2166.
Chien RN, Sheen IS, Chen TJ, Liaw YF 1992 A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121.
Choda Y, Morimoto Y, Miyaso H, Shinoura S, Saito S, Yagi T, Iwagaki H, Tanaka N 2004 Failure of the gut barrier system enhances liver injury in rats: protection of hepatocytes by gut-derived hepatocyte growth factor. Eur. J. Gastroenterol. Hepatol. 16: 1017-1025.
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ 2005 In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352.
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG 2008 Liver involvement in systemic lupus erythematosus: case review of 40 patients. J. Rheumatol. Sep 15 [Epub ahead of print].
Christensen E 2003 Prognosis of untreated primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 63. October 15-16. *
Chung YW, Sohn JH, Baek CH, Kim JP, Jeon YC, Han DS, Lee DH, Kee CS, Park IK 2006 Macro-aspartate aminotransferase in a patient with chronic hepatitis C. Korean J. Gastroenterol. 47: 229-232.
Cicek D, Kandi B, Demir B, Turgut D 2007 Intrahepatic cholestasis occurring with prurigo of pregnancy. Skinmed. 6: 298-301.
Clark JM, Brancati FL, Diehl AM 2003 The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98: 960-967. *
Collin M, Murch O, Thiemermann C 2006 Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia. Crit. Care Med. 34: 1131-1138.
Colombato LA, Alvarez F, Cote J, Huet PM 1994 Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 107: 1839-1843.
Colombo C, Setchell KD, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, Giunta A 1990 Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J. Pediatr. 117: 482-489.
Conti E, De Checchi G, Mencarelli R, Pinato S, Rovere P 2008 Lycopodium similiaplex-induced acute hepatitis: a case report. Eur. J. Gastroenterol. Hepatol. 20: 469-471.
Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, Chazouilleres O, Poupon R 2008 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48: 871-877.
Corpechot C, Benlian P, Barbu V, Chazouilleres O, Poupon RE, Poupon R 2001 Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J. Hepatol. 35: 324-328. *
Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chretien Y, Poupon RE, Poupon R 2004 Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 24: 187-193. *
Cox KL, Cox KM 1998 Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583.
Cravetto C, Molino G, Biondi AM, Cavanna A, Avagnina P, Frediani S 1985 Evaluation of the diagnostic value of serum bile acid in the detection and functional assessment of liver diseases. Ann. Clin. Biochem. 22: 596-605.
Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW 2008 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective? J. Hepatol. 48: 792-800. *
Czaja AJ 2006 Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55.
Czaja AJ 1999 Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70.
Czaja AJ 1999 Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 57: 49-68.
Czaja AJ, Beaver SJ, Wood JR, Klee GG, Go VL 1987 Frequency and significance of serum alpha-fetoprotein elevation in severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 93: 687-692.
Czaja AJ, Carpenter HA, Lindor KD 1999 Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30: 1381-1386. *
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 2000 Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 31: 1231-1238. *
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA 1993 Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J. Hepatol. 18: 342-352.
Czaja AJ, Nishioka M, Morshed SA, Hachiya T 1994 Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 107: 200-207.
Czaja AJ, Rakela J, Hay JE, Moore SB 1990 Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 98: 1587-1593.
Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT 2002 Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J. Hepatol. 37: 302-308. *
Czaja AJ, Taswell HF, Rakela J, Schimek CM 1990 Frequency and significance of antibody to hepatitis C virus in severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin. Proc. 65: 1303-1313.
Dann AT, Kenyon AP, Seed PT, Poston L, Shennan AH, Tribe RM 2004 Glutathione S-transferase and liver function in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 40: 1406-1414. *
Das SN, Mohapatra B, Mohanty R, Dash PC, Kar K, Dash PK 2007 Malarial hepatitis as a component of multiorgan failure - a bad prognostic sign. J. Indian Med. Assoc. 105: 247-250.
Daubioul CA, Horsmans Y, Lambert P, Danse E, Delzenne NM 2005 Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur. J. Clin. Nutr. 59: 723-726.
Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL 2008 Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr. 47: 61-67. *
Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL 2003 Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346. *
Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF 1982 Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin. Proc. 57: 303-309.
Day AP, Feher MD, Chopra R, Mayne PD 1993 The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42: 839-842.
de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ 2008 Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165. *
Deems RO, Friedman LS, Friedman MI, Munoz SJ, Deems DA, Maddrey WC 1994 Relationship between liver biochemical tests and dietary intake in patients with liver disease. J. Clin. Gastroenterol. 18: 304-308.
Degos F, Degott C, Erlinger S 1980 Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis. Gastroenterol. Clin. Biol. 4: 246-250.
Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, Guz G 2007 Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52: 3399-3403. *
Demirbilek S, Akin M, Gurunluoglu K, Aydin NE, Emre MH, Tas E, Aksoy RT, Ay S 2006 The NF-kappaB inhibitors attenuate hepatic injury in bile duct ligated rats. Pediatr. Surg. Int. 22: 655-663. *
Demirbilek S, Tas E, Gurunluoglu K, Akin M, Aksoy RT, Emre MH, Aydin NE, Ay S, Ozatay N 2007 Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr. Surg. Int. 23: 155-162. *
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *
Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK 2007 The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 27: 1402-1408. *
Dessein PH, Woodiwiss AJ, Joffe BI, Norton GR 2007 Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. BMC Cardiovasc. Disord. 7: 31. *
Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G 2005 Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 11: 441-448. *
Dinant S, Vetelainen RL, Florquin S, van Vliet AK, van Gulik TM 2007 IL-10 attenuates hepatic I/R injury and promotes hepatocyte proliferation. J. Surg. Res. 141: 176-182.
Ding Y, Zhao L, Mei H, Zhang SL, Huang ZH, Duan YY, Ye P 2008 Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. 590: 377-386.
Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F 1999 Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665.
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H 1999 Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98.
Dold S, Laschke MW, Lavasani S, Menger MD, Thorlacius H 2008 Cholestatic liver damage is mediated by lymphocyte function antigen-1-dependent recruitment of leukocytes. Surgery 144: 385-393.
Dong Z, Wei H, Sun R, Hu Z, Gao B, Tian Z 2004 Involvement of natural killer cells in PolyI:C-induced liver injury. J. Hepatol. 41: 966-973. *
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF 2003 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125: 298-303. *
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46: 2050-2068. *
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46: 2027-2049. *
Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver 2006 Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 4: 1537-1543.
Duvigneau JC, Piskernik C, Haindl S, Kloesch B, Hartl RT, Huttemann M, Lee I, Ebel T, Moldzio R, Gemeiner M, Redl H, Kozlov AV 2008 A novel endotoxin-induced pathway: upregulation of heme oxygenase 1, accumulation of free iron, and free iron-mediated mitochondrial dysfunction. Lab. Invest. 88: 70-77. *
Echard BW, Talpur NA, Fan AY, Bagchi D, Preuss HG 2001 Hepatoprotective ability of a novel botanical formulation on mild liver injury in rats produced by acute acetaminophen and/or alcohol ingestion. Res. Commun. Mol. Pathol. Pharmacol. 110: 73-85.
Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R 1998 Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol. Lett. 98: 13-23.
El-Beshbishy HA 2008 Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. Jun 20 [Epub ahead of print].
El-Karaksy HM, El-Hawary MI, El-Koofy NM, El-Sayed R, El-Raziky MA, Mansour SA, Taha GM, El-Mougy F 2006 Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. World J. Gastroenterol. 12: 7337-7340. *
Elinav E, Ben-Dov IZ, Ackerman E, Kiderman A, Glikberg F, Shapira Y, Ackerman Z 2005 Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. Am. J. Gastroenterol. 100: 2201-2204. *
Ellis G, Worthy E, Goldberg DM 1979 Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. Clin. Biochem. 12: 142-145.
Enns R, Eloubeidi MA, Mergener K, Jowell PS, Branch MS, Baillie J 2003 Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography. Can. J. Gastroenterol. 17: 243-248.
Epstein O, Arborgh B, Sagiv M, Wroblewski R, Scheuer PJ, Sherlock S 1981 Is copper hepatotoxic in primary biliary cirrhosis? J. Clin. Pathol. 34: 1071-1075. *
Epstein O, De Villiers D, Jain S, Potter BJ, Thomas HC, Sherlock S 1979 Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N. Engl. J. Med. 300: 274-278.
Epstein O, Jain S, Lee RG, Cook DG, Boss AM, Scheuer PJ, Sherlock S 1981 D-penicillamine treatment improves survival in primary biliary cirrhosis. Lancet 1: 1275-1277.
Epstein O, Sherlock S 1980 Triethylene tetramine dihydrochloride toxicity in primary biliary cirrhosis. Gastroenterology 78: 1442-1445.
Ercan I, Cakir BO, Basak T, Ozbal EA, Sahin A, Balci G, Turgut S 2006 Effects of topical application of methotrexate on nasal mucosa in rats: a preclinical assessment study. Otolaryngol. Head Neck Surg. 134: 751-755.
Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US 2005 Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 16: 124-128. *
Ertekin V, Selimoglu MA, Turkan Y, Akcay F 2005 Serum nitric oxide levels in children with celiac disease. J. Clin. Gastroenterol. 39: 782-785.
Evans HM, Kelly DA, McKiernan PJ, Hubscher S 2006 Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 43: 1109-1117. *
Evans J, Zerpa H, Nuttall L, Boss M, Sherlock S 1983 Copper chelation therapy in intrahepatic cholestasis of childhood. Gut 24: 42-48. *
Evensen KJ, Swaak TJ, Nossent JC 2007 Increased ferritin response in adult Still's disease: specificity and relationship to outcome. Scand. J. Rheumatol. 36: 107-110.
Fagundes ED, Roquete ML, Penna FJ, Reis FJ, Duque CG 2002 Diagnostic screening of liver disease in cystic fibrosis. J. Pediatr. (Rio. J.) 78: 389-396.
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ 2001 Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: 17-26.
Farkkila M, Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Niemela O 2008 Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int. 28: 787-797. *
Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L 2003 Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92: 794-797. *
Farver DK, Lavin MN 1999 Quinine-induced hepatotoxicity. Ann. Pharmacother. 33: 32-34.
Flores YN, Yee HF Jr, Leng M, Escarce JJ, Bastani R, Salmeron J, Morales LS 2008 Risk factors for chronic liver disease in blacks, Mexican Americans, and whites in the United States: results from NHANES IV, 1999-2004. Am. J. Gastroenterol. Jul 30 [Epub ahead of print]. *
Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH 2006 Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 44: 925-935. *
Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G 2008 Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J. Endocrinol. Invest. 31: 146-152.
Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB 1992 Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629.
Fu Y, Zheng S, Lin J, Ryerse J, Chen A 2008 Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73: 399-409. *
Fuentealba IC, Aburto EM 2003 Animal models of copper-associated liver disease. Comp. Hepatol. 2: 5. *
Fuhrmann V, Madl C, Mueller C, Holzinger U, Kitzberger R, Funk GC, Schenk P 2006 Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology 131: 69-75. *
Galhenage SP, Viiala CH, Olynyk JK 2004 Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51.
Galizzi J, Long RG, Billing BH, Sherlock S 1978 Assessment of the (14C) aminopyrine breath test in liver disease. Gut 19: 40-45. *
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J 1991 The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315.
Giannini E, Testa R 2000 Is aspartate aminotransferase enough? Am. J. Gastroenterol. 95: 3687-3688. *
Giboney PT 2005 Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 71: 1105-1110. *
Gilger MA, Gann ME, Opekun AR, Gleason WA Jr 2000 Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 31: 136-141. *
Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J 2007 Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114. *
Goldberg DM, Spooner RJ, Ellis G, Ward AM 1979 Biochemical features of intrahepatic cholestasis. Am. J. Clin. Pathol. 71: 557-563.
Granado M, Martin AI, Lopez-Menduina M, Lopez-Calderon A, Villanua MA 2008 GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia. Am. J. Physiol. Endocrinol. Metab. 294: E131-E141. *
Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, Blesa A, Montejo JC, Garcia de Lorenzo A, Mesejo A 2007 Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 11: R10. *
Griga T, Tromm A, Muller KM, May B 2000 Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases. Eur. J. Gastroenterol. Hepatol. 12: 559-564.
Grogan PM, Katz JS 2004 Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161.
Guslandi M 1990 Treatment of chronic liver disease with ursodeoxycholic acid. J. Int. Med. Res. 18: 497-505.
Halsted CH, Villanueva JA, Devlin AM 2002 Folate deficiency, methionine metabolism, and alcoholic liver disease. Alcohol 27: 169-172. *
Halsted CH, Villanueva JA, Devlin AM, Niemela O, Parkkila S, Garrow TA, Wallock LM, Shigenaga MK, Melnyk S, James SJ 2002 Folate deficiency disturbs hepatic methionine metabolism and promotes liver injury in the ethanol-fed micropig. Proc. Natl. Acad. Sci. U.S.A. 99: 10072-10077. *
Hanje AJ, Shamp JL, Thomas FB, Meis GM 2006 Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022. *
Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A 2007 Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin. Rheumatol. 26: 1867-1870. *
Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y 2008 A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin. Rheumatol. 27: 1063-1066.
Harrison J, McKiernan J, Neuberger JM 1997 A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl. Int. 10: 369-374.
Hasegawa M, Ide M, Fujita T, Takenaka S 2008 Urinary metabolic fingerprinting for alpha-naphthylisothiocyanate-induced intrahepatic cholestasis in rats using Fourier transform-ion cyclotron resonance mass spectrometry. Toxicol. Pathol. Sep 5 [Epub ahead of print]. *
Hasegawa T, Sakurai K, Kambayashi Y, Saniabadi AR, Nagamoto H, Tsukada K, Takahashi A, Kuwano H, Nakano M 2003 Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages. Surgery 134: 818-826. *
Hay JE, Czaja AJ, Rakela J, Ludwig J 1989 The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9: 193-197.
Heathcote J, Ross A, Sherlock S 1976 A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660.
Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D 1999 Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407. *
Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, Heaton ND, O'Grady JG 2001 Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 34: 464-470. *
Herrine SK 2003 Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Higuchi S, Wu R, Zhou M, Marini CP, Ravikumar TS, Wang P 2008 Gut hyperpermiability after ischemia and reperfusion: attenuation with adrenomedullin and its binding protein treatment. Int. J. Clin. Exp. Pathol. 1: 409-418.
Higuchi S, Wu R, Zhou M, Ravikumar TS, Wang P 2007 Downregulation of hepatic cytochrome P-450 isoforms and PPAR-gamma: their role in hepatic injury and proinflammatory responses in a double-hit model of hemorrhage and sepsis. J. Surg. Res. 137: 46-52. *
Hino T, Kumashiro R, Ide T, Koga Y, Ishii K, Tanaka E, Morita Y, Hisamochi A, Murashima S, Tanaka K, Ogata K, Kuwahara R, Sata M 2003 Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int. J. Mol. Med. 11: 749-755.
Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, Lee SD 2004 Fenofibrate-induced acute cholestatic hepatitis. J. Chin. Med. Assoc. 67: 245-247. *
Honjo S, Kono S, Coleman MP, Shinchi K, Sakurai Y, Todoroki I, Umeda T, Wakabayashi K, Imanishi K, Nishikawa H, Ogawa S, Katsurada M, Nakagawa K, Yoshizawa N 2001 Coffee consumption and serum aminotransferases in middle-aged Japanese men. J. Clin. Epidemiol. 54: 823-829.
Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG, Minuk GY, Dusheiko GM, Campbell G, et al 1986 Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91: 1327-1334.
Horiguchi N, Ishac EJ, Gao B 2007 Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol 41: 271-280.
Hu KQ, Kyulo NL, Lim N, Elhazin B, Hillebrand DJ, Bock T 2004 Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 99: 860-865. *
Huang MJ, Liaw YF 1995 Clinical associations between thyroid and liver diseases. J. Gastroenterol. Hepatol. 10: 344-350.
Huang YT, Hsu YC, Chen CJ, Liu CT, Wei YH 2003 Oxidative-stress-related changes in the livers of bile-duct-ligated rats. J. Biomed. Sci. 10: 170-178. *
Huet PM, Vincent C, Deslaurier J, Cote J, Matsutami S, Boileau R, Huet J 2008 Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology Jul 23 [Epub ahead of print]. *
Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, Ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE 2008 Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135: 32-40. *
Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ 1993 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223.
Ikeda E, Yagi K, Kojima M, Yagyuu T, Ohshima A, Sobajima S, Tadokoro M, Katsube Y, Isoda K, Kondoh M, Kawase M, Go MJ, Adachi H, Yokota Y, Kirita T, Ohgushi H 2008 Multipotent cells from the human third molar: feasibility of cell-based therapy for liver disease. Differentiation 76: 495-505.
Ikeda T, Sato C, Noguchi O, Kobayashi F, Tozuka S, Sakamoto S, Marumo F 1996 Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy. J. Gastroenterol. Hepatol. 11: 366-372.
Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, Sato C 1996 Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J. Hepatol. 24: 88-94. *
Ioannou GN, Boyko EJ, Lee SP 2006 The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999�2002. Am. J. Gastroenterol. 101: 76-82. *
Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD 2007 Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am. J. Surg. Pathol. 31: 607-614.
Isai H, Sheil AG, McCaughan G, Dolan P, Waugh R 1992 Successful reversal of primary graft non-function in a liver transplant patient treated with prostaglandin E1. Aust. N.Z. J. Surg. 62: 314-316.
Iseri SO, Sener G, Ercan F, Gedik N, Yegen BC 2008 Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats. Regul. Pept. 146: 73-79.
Ishibashi E, Eguchi Y, Eguchi T, Matsunobu A, Oza N, Nakashita S, Kitajima Y, Kuroki S, Ozaki I, Kawaguchi Y, Ide Y, Yasutake T, Iwakiri R, Mizuta T, Ono N, Fujimoto K 2008 Waist circumference correlates with hepatic fat accumulation in male Japanese patients with non-alcoholic fatty liver disease, but not in females. J. Gastroenterol. Hepatol. 23: 908-913. *
Ishizaki M, Kaibori M, Uchida Y, Hijikawa T, Tanaka H, Ozaki T, Tokuhara K, Matsui K, Kwon AH, Kamiyama Y, Nishizawa M, Okumura T 2008 Protective effect of FR183998, a Na+/H+ exchanger inhibitor, and its inhibition of iNOS induction in hepatic ischemia-reperfusion injury in rats. Shock 30: 311-317.
Ito K, Ozasa H, Noda Y, Arii S, Horikawa S 2008 Effects of free radical scavenger on acute liver injury induced by d-galactosamine and lipopolysaccharide in rats. Hepatol. Res. 38: 194-201. *
Ito S, Yukawa T, Uetake S, Yamauchi M 2007 Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87. *
Iwai M, Jo M, Ishii M, Mori T, Harada Y 2008 Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol. Res. 38: 784-789. *
Iwasaki S, Akisawa N, Saibara T, Onishi S 2007 Fibrate for treatment of primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S515-S517. *
Jacobsen MB, Fausa O, Elgjo K, Schrumpf E 1990 Hepatic lesions in adult coeliac disease. Scand. J. Gastroenterol. 25: 656-662.
Jadaho SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, Gong DW 2004 Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology 39: 1297-1302. *
Jain S, Scheuer PJ, Samourian S, McGee JO 1977 A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet 1: 831-834.
Johnson K, Kotiesh A, Boitnott JK, Torbenson M 2007 Histology of symptomatic acute hepatitis C infection in immunocompetent adults. Am. J. Surg. Pathol. 31: 1754-1758.
Jun SY, Kim JS, Yu E 2002 Primary sclerosing cholangitis - a report of two liver explants. Korean J. Pathol. 36: 420-424. *
Kakumu S 2004 Is mortality from liver disease associated with normal serum aminotransferase concentrations? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 2-3. *
Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, Fukushima S 2008 Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol. Appl. Pharmacol. 228: 295-300. *
Kao JH, Lai MY, Lin JT, Yang PM, Sheu JC, Chen DS, Sung JL, Wang TH 1991 Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis. J. Formos. Med. Assoc. 90: 970-974.
Karaman A, Iraz M, Kirimlioglu H, Karadag N, Tas E, Fadillioglu E 2006 Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment. Pediatr. Surg. Int. 22: 701-708. *
Karan B, Kama NA, Hascelik G, Ercan M 1996 Effects of vitamin A on immunological deficiencies in rats with obstructive jaundice. Eur. J. Surg. 162: 217-222.
Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H 2005 Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121. *
Kashireddy PR, Rao MS 2004 Sex differences in choline-deficient diet-induced steatohepatitis in mice. Exp. Biol. Med. (Maywood) 229: 158-162. *
Kashireddy PV, Rao MS 2004 Lack of peroxisome proliferator-activated receptor a in mice enhances methionine and choline deficient diet-induced steatohepatitis. Hepatol. Res. 30: 104-110.
Kaya E, Dervisoglu A, Polat C 2007 Evaluation of diagnostic findings and scoring systems in outcome prediction in acute pancreatitis. World J. Gastroenterol. 13: 3090-3094. *
Keeffe EB, Davis GL 2004 Advances in Liver Disease: Highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42. *
Kim SK, Kim YC 2002 Attenuation of bacterial lipopolysaccharide-induced hepatotoxicity by betaine or taurine in rats. Food Chem. Toxicol. 40: 545-549. *
Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J, Therneau TM, Malinchoc M, Dickson ER 1999 The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29: 1643-1648. *
Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, Lindor KD, Dickson ER 2000 A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75: 688-694. *
Kim YC, Jung YS, Kim SK 2005 Effect of betaine supplementation on changes in hepatic metabolism of sulfur-containing amino acids and experimental cholestasis induced by alpha-naphthylisothiocyanate. Food Chem. Toxicol. 43: 663-670. *
Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y 2003 Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278: 17838-17844. *
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F 2003 Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718.
Klingenberg S, Chen W 2006 D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 1: CD004182. *
Knox TA, Kaplan MM 1991 Treatment of primary sclerosing cholangitis with oral methotrexate. Am. J. Gastroenterol. 86: 546-552.
Kondrackiene J, Beuers U, Kupcinskas L 2005 Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129: 894-901. *
Kornberg A, Schotte U, Kupper B, Hommann M, Scheele J 2004 Impact of selective prostaglandin E1 treatment on graft perfusion and function after liver transplantation. Hepatogastroenterology 51: 526-531.
Kotila T, Adedapo K, Adedapo A, Oluwasola O, Fakunle E, Brown B 2005 Liver dysfunction in steady state sickle cell disease. Ann. Hepatol. 4: 261-263.
Kremer M, Hines IN, Milton RJ, Wheeler MD 2006 Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis. Hepatology 44: 216-227. *
Labib R, Turkall R, Abdel-Rahman MS 2002 Endotoxin potentiates the hepatotoxicity of cocaine in male mice. J. Toxicol. Environ. Health A. 65: 977-993.
Lakatos PL, Firneisz G, Borcsiczky D, Zalatnai A, Selmeci L, Szalay F 2000 Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur. J. Clin. Invest. 30: 793-797.
Laschke MW, Menger MD, Wang Y, Lindell G, Jeppsson B, Thorlacius H 2007 Sepsis-associated cholestasis is critically dependent on P-selectin-dependent leukocyte recruitment in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1396-G1402. *
Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB 1996 Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464-1467. *
Lazaridis KN, LaRusso NF 2003 Bile formation: do not ignore the role of plasma membrane-cytoskeleton linking proteins. Hepatology 37: 218-220. *
Lazo M, Selvin E, Clark JM 2008 Brief communication: clinical implications of short-term variability in liver function test results. Ann. Intern. Med. 148: 348-352.
Lee JY, Jung da W, Park HA, Kim SJ, Chung JH, Moon CK, Kim YC 2004 Effect of taurine on biliary excretion and metabolism of acetaminophen in male hamsters. Biol. Pharm. Bull. 27: 1792-1796. *
Lee NC, Chien YH, Kobayashi K, Saheki T, Chen HL, Chiu PC, Ni YH, Chang MH, Hwu WL 2006 Time course of acylcarnitine elevation in neonatal intrahepatic cholestasis caused by citrin deficiency. J. Inherit. Metab. Dis. 29: 551-555. *
Lee YS, Cho YK, Pae JC, Oh SY, Kang MS, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Lee WY, Oh KW, Yun EJ, Oh ES 2006 The relationship between serum adiponectin level and serum alanine aminotransferase elevation in Korean male with nonalcoholic fatty liver disease. Korean J. Hepatol. 12: 221-229.
Lepage G, Paradis K, Lacaille F, Senechal L, Ronco N, Champagne J, Lenaerts C, Roy CC, Rasquin-Weber A 1997 Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J. Pediatr. 130: 52-58. *
Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, Gatzen M, Leuschner M 1989 Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 97: 1268-1274.
Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L 1999 Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J. Pediatr. Endocrinol. Metab. 12: 549-553.
Levy C, Lindor KD 2003 Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37. *
Levy C, Lindor KD 2003 Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498.
Lewis JH, Ahmed M, Shobassy A, Palese C 2006 Drug-induced liver disease. Curr. Opin. Gastroenterol. 22: 223-233.
Li GX, Pei QL, Gao Y, Liu KM, Nie JS, Han G, Qiu YL, Zhang WP 2007 Protective effects of hepatocellular canalicular conjugate export pump (Mrp2) on sodium arsenite-induced hepatic dysfunction in rats. Exp. Toxicol. Pathol. 58: 447-453. *
Li N, Zhang H, Wang S, Zhu W, Ren J, Li J 2002 Laboratory investigation and clinical application of S-adenosyl-L-methionine in the treatment of cholestasis after total parenteral nutrition. Zhonghua Wai Ke Za Zhi 40: 407-410.
Lian XL, Bai Y, Dai WX, Guo ZS, Li W, Lu L 2004 Propylthiouracil-induced overt hepatic injury in patients with hyperthyroidism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 26: 172-177.
Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R 2008 Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin. Exp. Med. 8: 1-7. *
Lichtman SN, Okoruwa EE, Keku J, Schwab JH, Sartor RB 1992 Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J. Clin. Invest. 90: 1313-1322. *
Lieber CS 2002 S-Adenosyl-L-methionine and alcoholic liver disease in animal models: implications for early intervention in human beings. Alcohol 27: 173-177. *
Lieber CS 1990 Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease. Drugs 40 Suppl. 3: 23-44.
Lieber CS, Weiss DG, Morgan TR, Paronetto F 2006 Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am. J. Gastroenterol. 101: 1500-1508. *
Lin CF, Wan SW, Chen MC, Lin SC, Cheng CC, Chiu SC, Hsiao YL, Lei HY, Liu HS, Yeh TM, Lin YS 2008 Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Lab. Invest. Aug 4 [Epub ahead of print]. *
Lin SC, Shyur SD, Ma YC, Huang LH, Lee HC, Lee WI 2005 Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J. Formos. Med. Assoc. 104: 421-426.
Lindor KD 1997 Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 336: 691-695. *
Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA 2003 Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112: 1678-1687. *
Ljubuncic P, Konikoff FM, Blendis LM, Bomzon A 2005 Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection. Hepatogastroenterology 52: 1191-1196.
Lopez-Mendez E, Lopez-Mendez E, Lopez-Mendez I, Hernandez-Reyes P, Galindo-Uribe J, Angulo-Ramirez V, Avila-Escobedo L, Uribe M 2006 A 57 year old man with chronic renal failure and cardiac tamponade who developed ischemic hepatitis. Ann. Hepatol. 5: 50-52.
Lotterer E, Stiehl A, Raedsch R, Foelsch UR, Bircher J 1990 Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III. J. Hepatol. 10: 284-290.
Lukivskaya O, Zavodnik L, Knas M, Buko V 2006 Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51: 54-59.
Luth S, Herkel J, Kanzler S, Frenzel C, Galle PR, Dienes HP, Schramm C, Lohse AW 2008 Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol. 42: 926-930.
Luyendyk JP, Shores KC, Ganey PE, Roth RA 2002 Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 68: 220-225. *
Lv X, Li Q, Huang SD, Wu FX, Yang LQ, Yu WF 2008 Isoflurane pretreatment reduced liver injury induced by ischemia/reperfusion combined with lipopolysaccharide in rats. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 20: 271-274.
Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D 2006 Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type-2. Gastroenterology 130: 868-882. *
Mackay IR 1987 Treatment of chronic active hepatitis and other liver diseases with corticosteroid agents. Med. J. Aust. 146: 370-374.
Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA 1998 The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 35: 99-103.
Magnani HN, Alaupovic P 1976 Utilization of the quantitative assay of lipoprotein X in the differential diagnosis of extraphepatic obstructive jaundice and intrahepatic diseases. Gastroenterology 71: 87-93.
Mahadevan U, Sandborn WJ 2001 Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476.
Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T 2006 Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54: 2817-2829. *
Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO 2005 Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42: 1091-1098. *
Mancilla AC, Madrid SAM, Valenzuela EJ, Morales BA, Hurtado HC, Smok SG, Ledezma RR, Castillo MI, Rivas QM, Brahm BJ 2005 Adult celiac disease: clinical experience. Rev. Med. Chil. 133: 1317-1321.
Manso MA, Ramudo L, De Dios I 2007 Extrapancreatic organ impairment during acute pancreatitis induced by bile-pancreatic duct obstruction. Effect of N-acetylcysteine. Int. J. Exp. Pathol. 88: 343-349.
Marcellini M, Di Ciommo V, Callea F, Devito R, Comparcola D, Sartorelli MR, Carelli F, Nobili V 2005 Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J. Lab. Clin. Med. 145: 139-143.
Marcy TR, Britton ML, Blevins SM 2004 Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 38: 1419-1423.
Mason A, Nair S 2002 Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr. Gastroenterol. Rep. 4: 45-51.
Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G 1999 The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand. J. Gastroenterol. 34: 85-91. *
Matloff DS, Alpert E, Resnick RH, Kaplan MM 1982 A prospective trial of D-penicillamine in primary biliary cirrhosis. N. Engl. J. Med. 306: 319-326.
Matsuda Y, Amuro Y, Hada T, Higashino K, Ueki N, Fujikura M, Tonomura A, Yamamoto T, Yamaguchi K, Shimomura S, et al 1994 Aspartate aminotransferase-linked immunoglobulin complexes in serum of a patient with primary biliary cirrhosis. J. Gastroenterol. 29: 218-222.
Matsui H, Ikeda K, Nakajima Y, Horikawa S, Imanishi Y, Kawada N 2004 Sulfur-containing amino acids attenuate the development of liver fibrosis in rats through down-regulation of stellate cell activation. J. Hepatol. 40: 917-925. *
Matsumoto T, Suzuki N, Watanabe H, Irie M, Iwata K, Anan A, Nakane H, Yoshikane M, Nishizawa S, Sohda T, Sakisaka S 2004 Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 39: 1102-1105. *
McCune CA, Ravine D, Carter K, Jackson HA, Hutton D, Hedderich J, Krawczak M, Worwood M 2006 Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 55: 554-562. *
McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR 2005 National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin. Infect. Dis. 41: 1134-1142. *
McMichael J, Lieberman R, McCauley J, Irish W, Marino I, Doyle H 1996 Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther. Drug Monit. 18: 435-437.
Michaels A, Levy C 2008 The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61.
Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM, Heathcote EJ 1994 Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 35: 260-265. *
Migita K, Abiru S, Maeda Y, Nakamura M, Komori A, Ito M, Fujiwara S, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H 2007 Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum. Immunol. 68: 586-591.
Mikami KI, Otaka M, Goto T, Miura K, Ohshima S, Yoneyama K, Lin JG, Watanabe D, Segawa D, Kataoka E, Odashima M, Watanabe S 2004 Induction of a 72-kDa heat shock protein and protection against lipopolysaccharide-induced liver injury in cirrhotic rats. J. Gastroenterol. Hepatol. 19: 884-890. *
Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E 2003 Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J. Gastroenterol. Hepatol. 18: 1283-1286. *
Milkiewicz P, Saksena S, Cardenas T, Mills CO, Elias E 2000 Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis. Liver 20: 330-334.
Milkiewicz P, Saksena S, Hubscher SG, Elias E 2000 Wilson's disease with superimposed autoimmune features: report of two cases and review. J. Gastroenterol. Hepatol. 15: 570-574. *
Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J, Van Thiel DH 2003 Prochlorperazine-induced cholestasis in a patient with alpha-1 antitrypsin deficiency. Hepatogastroenterology 50: 1338-1340.
Miyake Y, Iwasaki Y, Terada R, Nagano T, Kobashi H, Sakaguchi K, Shiratori Y 2008 A model for estimating cirrhosis in patients with type 1 autoimmune hepatitis. Hepatol. Res. 38: 658-663. *
Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Kobashi H, Sakaguchi K, Shiratori Y 2007 Clinical features of Japanese type 1 autoimmune hepatitis patients with zone III necrosis. Hepatol. Res. 37: 801-805. *
Miyaso H, Morimoto Y, Ozaki M, Haga S, Shinoura S, Choda Y, Iwagaki H, Tanaka N 2005 Obstructive jaundice increases sensitivity to lipopolysaccharide via TLR4 upregulation: possible involvement in gut-derived hepatocyte growth factor-protection of hepatocytes. J. Gastroenterol. Hepatol. 20: 1859-1866. *
Miyata M, Tozawa A, Otsuka H, Nakamura T, Nagata K, Gonzalez FJ, Yamazoe Y 2005 Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity. J. Pharmacol. Exp. Ther. 312: 759-766. *
Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, Yamazoe Y 2006 Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. Xenobiotica 36: 631-644. *
Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E 2008 Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 57: 387-392. *
Montano-Loza AJ, Carpenter HA, Czaja AJ 2007 Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol. 102: 1005-1012. *
Morrison ED, Brandhagen DJ, Phatak PD, Barton JC, Krawitt EL, El-Serag HB, Gordon SC, Galan MV, Tung BY, Ioannou GN, Kowdley KV 2003 Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann. Intern. Med. 138: 627-633. *
Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N 1998 Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273: 16710-16714. *
Moyer MS, Graeme-Cook FM 2002 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2002. A 17-year-old boy with biliary obstruction. N. Engl. J. Med. 346: 271-276.
Mulder TP, Janssens AR, de Bruin WC, Peters WH, Cooreman MP, Jansen JB 1997 Plasma glutathione S-transferase alpha 1-1 levels in patients with chronic liver disorders. Clin. Chim. Acta 258: 69-77. *
Murch O, Collin M, Thiemermann C 2007 Lysophosphatidic acid reduces the organ injury caused by endotoxemia - a role for G-protein-coupled receptors and peroxisome proliferator-activated receptor-gamma. Shock 27: 48-54. *
Murphy JR, Sjogren MH, Kikendall JW, Peura DA, Goodman Z 1990 Small bile duct abnormalities in sarcoidosis. J. Clin. Gastroenterol. 12: 555-561.
Nair S, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP 2004 Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther. 20: 23-28. *
Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I 1998 Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 13: 490-495.
Nan JX, Jin XJ, Lian LH, Cai XF, Jiang YZ, Jin HR, Lee JJ 2008 A diterpenoid acanthoic acid from Acanthopanax koreanum protects against D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice. Biol. Pharm. Bull. 31: 738-742. *
Nathwani RA, Kumar SR, Reynolds TB, Kaplowitz N 2005 Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am. J. Gastroenterol. 100: 295-298. *
Nathwani RA, Pais S, Reynolds TB, Kaplowitz N 2005 Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 41: 380-382. *
Neff GW, O'Brien C, Montalbano M, DeManno A, Kahn S, Safdar K, Nishida S, Tzakis A 2004 Consumption of dietary supplements in a liver transplant population. Liver Transpl. 10: 881-885. *
Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM, Tzakis AG, O'Brien CB 2004 Sirolimus-associated hepatotoxicity in liver transplantation. Ann. Pharmacother. 38: 1593-1596.
Net M, Valero R, Almenara R, Barros P, Capdevila L, Lopez-Boado MA, Ruiz A, Sanchez-Crivaro F, Miquel R, Deulofeu R, Taura P, Manyalich M, Garcia-Valdecasas JC 2005 The effect of normothermic recirculation is mediated by ischemic preconditioning in NHBD liver transplantation. Am. J. Transplant. 5: 2385-2392. *
Neuschwander-Tetri BA 2000 Nonalcoholic steatohepatitis: an evolving diagnosis. Can. J. Gastroenterol. 14: 321-326.
Neyrinck AM, Mouson A, Delzenne NM 2007 Dietary supplementation with laminarin, a fermentable marine beta (1-3) glucan, protects against hepatotoxicity induced by LPS in rat by modulating immune response in the hepatic tissue. Int. Immunopharmacol. 7: 1497-1506.
Niederau C, Lange S, Fruhauf M, Thiel A 2008 Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis. Liver Int. 28: 659-666. *
Nieto N 2007 Ethanol and fish oil induce NFkappaB transactivation of the collagen alpha2(I) promoter through lipid peroxidation-driven activation of the PKC-PI3K-Akt pathway. Hepatology 45: 1433-1445. *
Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, Morita A, Kashima K 2001 Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin. Exp. Immunol. 123: 271-279. *
Nobili V 2003 Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data. Pediatr. Transplant. 7: 454-457.
Novinscak T, Brcic L, Staresinic M, Jukic I, Radic B, Pevec D, Mise S, Tomasovic S, Brcic I, Banic T, Jakir A, Buljat G, Anic T, Zoricic I, Romic Z, Seiwerth S, Sikiric P 2008 Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg. Today 38: 716-725.
Nowak U, Gill K, Skamene E, Newkirk MM 2007 Rheumatoid factor induction in murine models of liver injury. Clin. Exp. Immunol. 147: 324-329. *
Nyblom H, Bjornsson E, Simren M, Aldenborg F, Almer S, Olsson R 2006 The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int. 26: 840-845. *
Nyblom H, Nordlinder H, Olsson R 2007 High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int. 27: 694-699. *
Ochiai K, Muramatsu H, Yamamoto S, Ando H, Muramatsu T 2004 The role of midkine and pleiotrophin in liver regeneration. Liver Int. 24: 484-491. *
Ohata M, Suzuki H, Sakamoto K, Hashimoto K, Nakajima H, Yamauchi M, Hokkyo K, Yamada H, Toda G 2004 Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin. Exp. Res. 28: 139S-144S.
Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T, et al 1990 A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn. 25: 774-780.
Okada T, Morise T, Takeda Y, Mabuchi H 2000 A new variant deletion of a copper-transporting P-type ATPase gene found in patients with Wilson's disease presenting with fulminant hepatic failure. J. Gastroenterol. 35: 278-283. *
Okita H, Ohtsuka T, Yamakage A, Yamazaki S 2002 Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch. Dermatol. Res. 294: 159-162. *
Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G 1996 Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur. J. Gastroenterol. Hepatol. 8: 685-691.
Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, Colombo M, Galatola G, Gasbarrini G, Podda M, Ricci G, Rosina F, Zuin M 2003 Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig. Liver Dis. 35: 325-331.
Okumura H, Katoh M, Minami K, Nakajima M, Yokoi T 2007 Change of drug excretory pathway by CCl(4)-induced liver dysfunction in rat. Biochem. Pharmacol. 74: 488-495. *
Okunuki Y, Usui Y, Kezuka T, Hattori T, Masuko K, Nakamura H, Yudoh K, Goto H, Usui M, Nishioka K, Kato T, Takeuchi M 2008 Proteomic surveillance of retinal autoantigens in endogenous uveitis: implication of esterase D and brain-type creatine kinase as novel autoantigens. Mol. Vis. 14: 1094-1104.
Olsson R, Broome U, Danielsson A, Hagerstrand I, Jarnerot G, Loof L, Prytz H, Ryden BO, Wallerstedt S 1995 Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 108: 1199-1203. *
Omagari K, Masuda J, Kato Y, Nakata K, Kanematsu T, Kusumoto Y, Mori I, Furukawa R, Tanioka H, Tajima H, Koga M, Yano M, Kohno S 2000 Re-analysis of clinical features of 89 patients with autoimmune hepatitis using the revised scoring system proposed by the International Autoimmune Hepatitis Group. Intern. Med. 39: 1008-1012. *
Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H 2007 A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56: 1747-1753. *
Ozden I, Kara M, Pinarbasi B, Salmaslioglu A, Yavru A, Kaymakoglu S, Emre A, Bilge O, Alper A 2007 Somatostatin and propranolol to treat small-for-size syndrome that occurred despite splenic artery ligation. Exp. Clin. Transplant. 5: 686-689.
Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, Liepins J, Lira F, Sedano M, Silva O, Toha D, Silva JJ 1997 Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27: 1022-1028. *
Panasiuk A, Zak J, Panasiuk B, Prokopowicz D 2007 Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis. Blood Coagul. Fibrinolysis 18: 739-744.
Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M 2004 Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57. *
Paredes AH, Lewis JH 2007 Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann. Pharmacother. 41: 880-884.
Pari L, Sivasankari R 2008 Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. Fundam. Clin. Pharmacol. 22: 395-401.
Parveen S, Morshed SA, Arima K, Nishioka M, Czaja AJ, Chow WC, Ng HS 1998 Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association. Dig. Dis. Sci. 43: 1322-1331. *
Patriquin H, Lenaerts C, Smith L, Perreault G, Grignon A, Filiatrault D, Boisvert J, Roy CC, Rasquin-Weber A 1999 Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 211: 229-232. *
Patt CH, Yoo HY, Dibadj K, Flynn J, Thuluvath PJ 2003 Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig. Dis. Sci. 48: 797-801. *
Pazzi P, Puviani AC, Dalla Libera M, Guerra G, Ricci D, Gullini S, Ottolenghi C 1997 Bile salt-induced cytotoxicity and ursodeoxycholate cytoprotection: in-vitro study in perifused rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 9: 703-709.
Penalva Polo JC, Verdu Benavente C, Belda Abad G, Ruiz JA, Gaspar Martinez E, Correa Estan JA, Munoz Ramirez E, Martinez Prieto C 2006 Persistent acute hepatitis in a patient with chronic hepatitis C. Gastroenterol. Hepatol. 29: 451-454.
Peterson JR, Hsu FC, Simkin PA, Wener MH 2003 Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann. Rheum. Dis. 62: 1078-1082. *
Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkstrom V, Ekelund M 2008 Muscular exercise can cause highly pathological liver function tests in healthy men. Br. J. Clin. Pharmacol. 65: 253-359. *
Plodziszewska M, Slodkowska J, Orlowski T, Pawlicka L, Rowinska-Zakrzewska E 1998 Primary biliary cirrhosis with sarcoid-like infiltrations in the lung. Pneumonol. Alergol. Pol. 66: 330-336.
Pometta R, Callea F, Mangano M, Zuccoli E, Conte D 2000 Recurrent cholestasis and hypereosinophilia in a young female. Dig. Liver Dis. 32: 630-633.
Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP 2005 Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16. *
Poupon R, Chazouilleres O, Balkau B, Poupon RE 1999 Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J. Hepatol. 30: 408-412. *
Poupon RE, Balkau B, Eschwege E, Poupon R 1991 A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554.
Poupon RE, Eschwege E, Poupon R 1990 Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J. Hepatol. 11: 16-21.
Prall RT, Lindor KD, Wiesner RH, LaRusso NF 2000 Current therapies and clinical controversies in the management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 2: 99-103.
Puhl G, Schaser KD, Pust D, Kohler K, Vollmar B, Menger MD, Neuhaus P, Settmacher U 2005 Initial hepatic microcirculation correlates with early graft function in human orthotopic liver transplantation. Liver Transpl. 11: 555-563. *
Pulitano C, Aldrighetti L, Arru M, Finazzi R, Soldini L, Catena M, Ferla G 2007 Prospective randomized study of the benefits of preoperative corticosteroid administration on hepatic ischemia-reperfusion injury and cytokine response in patients undergoing hepatic resection. HPB (Oxford) 9: 183-189. *
Rahman SM, Schroeder-Gloeckler JM, Janssen RC, Jiang H, Qadri I, Maclean KN, Friedman JE 2007 CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 45: 1108-1117. *
Rajendra S, Kutty K 2005 Caecal tumour with hepatic metastases? Gut 54: 178. *
Ramirez-Farias C, Madrigal-Santillan E, Gutierrez-Salinas J, Rodriguez-Sanchez N, Martinez-Cruz M, Valle-Jones I, Gramlich-Martinez I, Hernandez-Ceruelos A, Morales-Gonzalez JA 2008 Protective effect of some vitamins against the toxic action of ethanol on liver regeneration induced by partial hepatectomy in rats. World J. Gastroenterol. 14: 899-907. *
Rasmussen HH, Fallingborg J, Mortensen PB, Freund L, Tage-Jensen U, Kruse V, Rasmussen SN 1992 Primary sclerosing cholangitis in patients with ulcerative colitis. Scand. J. Gastroenterol. 27: 732-736.
Ricchi M, Bertolotti M, Anzivino C, Carulli L, Canedi I, Bormioli ML, Tiozzo R, Croce MA, Lonardo A, Carulli N, Loria P 2006 17beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. J. Gastroenterol. Hepatol. 21: 894-901. *
Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M 2002 Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Ther. 7: 219-226.
Roda E, Azzaroli F, Nigro G, Piazza F, Jaboli F, Ferrara F, Liva S, Giovanelli S, Miracolo A, Colecchia A, Festi D, Mazzeo C, Bacchi L, Roda A, Mazzella G 2002 Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig. Liver Dis. 34: 523-527.
Rodriguez-Hernandez H, Gonzalez JL, Marquez-Ramirez MD, Flores-Hernandez M, Rodriguez-Moran M, Guerrero-Romero F 2008 Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur. J. Gastroenterol. Hepatol. 20: 399-403.
Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T 1991 Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur. J. Clin. Pharmacol. 40: 473-476.
Roncaglia N, Locatelli A, Arreghini A, Assi F, Cameroni I, Pezzullo JC, Ghidini A 2004 A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG 111: 17-21.
Rudow DL, Brown RS Jr, Emond JC, Marratta D, Bellemare S, Kinkhabwala M 2004 One-year morbidity after donor right hepatectomy. Liver Transpl. 10: 1428-1431. *
Ruhnke M, Nussler AK, Ungefroren H, Hengstler JG, Kremer B, Hoeckh W, Gottwald T, Heeckt P, Fandrich F 2005 Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 79: 1097-1103.
Rutherford AE, Pratt DS 2006 Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214.
Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, Tschuschner A, Gressner OA, Weiskirchen R, Graf J, Roeb E 2008 Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab. Invest. Sep 15 [Epub ahead of print]. *
Salvino R, Ghanta R, Seidner DL, Mascha E, Xu Y, Steiger E 2006 Liver failure is uncommon in adults receiving long-term parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 30: 202-208. *
Sanchez O, Viladrich M, Ramirez I, Soley M 2007 Liver injury after an aggressive encounter in male mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1908-R1916. *
Sawa H, Ueda T, Takeyama Y, Yasuda T, Shinzeki M, Nakajima T, Kuroda Y 2007 Role of Toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice. Surg. Today 37: 867-873.
Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S 2008 Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. May 9 [Epub ahead of print]. *
Schemmer P, Liang R, Kincius M, Flechtenmacher C, Bunzendahl H, Gutt CN, Mehrabi A, Gebhard MM, Buchler MW, Kraus TW 2005 Taurine improves graft survival after experimental liver transplantation. Liver Transpl. 11: 950-959. *
Schneider SM, Joly F, Gehrardt MF, Badran AM, Myara A, Thuillier F, Coudray-Lucas C, Cynober L, Trivin F, Messing B 2006 Taurine status and response to intravenous taurine supplementation in adults with short-bowel syndrome undergoing long-term parenteral nutrition: a pilot study. Br. J. Nutr. 96: 365-370. *
Schuppan D, Jia JD, Brinkhaus B, Hahn EG 1999 Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104. *
Scully C, Potts AJ, Hamburger J, Wiesenfeld D, McKee JI, el Kom M 1985 Lichen planus and liver disease: how strong is the association? J. Oral. Pathol. 14: 224-226.
Selimoglu MA, Ertekin V, Altinkaynak S 2007 Hyper-CK-emia in pediatric celiac disease: prevalence and clinical importance. J. Clin. Gastroenterol. 41: 667-670.
Sen M, Inan A, Yenidunya S, Ergin M, Dener C 2006 Effect of vitamin A on the CD44 expression in the small intestine of rats with obstructive jaundice. Eur. Surg. Res. 38: 347-352.
Sener G, Sehirli AO, Gedik N, Dulger GA 2007 Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 33: 587-593.
Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H 2006 Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl. Int. 19: 919-926. *
Serfaty L 2007 Pioglitazone: the beginning of a new era for NASH? J. Hepatol. 47: 160-162. *
Sharma RP, He Q, Riley RT 2005 Lupus-prone NZBWF1/J mice, defective in cytokine signaling, are resistant to fumonisin hepatotoxicity despite accumulation of liver sphinganine. Toxicology 216: 59-71. *
Sheehan M, Haythorn P 1979 Predictive values of various liver function tests with respect to the diagnosis of liver disease. Clin. Biochem. 12: 262-263.
Shiels MT, Czaja AJ, Ludwig J, McCullough AJ, Jones JD, Go VL 1985 Diagnostic and prognostic implications of plasma amino acid determinations in chronic active hepatitis. Dig. Dis. Sci. 30: 819-823.
Shiraishi M, Ichiyama T, Matsushige T, Iwaki T, Iyoda K, Fukuda K, Makata H, Matsubara T, Furukawa S 2008 Soluble tumor necrosis factor receptor 1 and tissue inhibitor of metalloproteinase-1 in hemolytic uremic syndrome with encephalopathy. J. Neuroimmunol. 196: 147-152.
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P 2006 The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit. Care Med. 34: 1874-1882.
Sijens PE, Alkefaji H, Lunsing RJ, van Spronsen FJ, Meiners LC, Oudkerk M, Verkade HJ 2008 Quantitative multivoxel (1)H MR spectroscopy of the brain in children with acute liver failure. Eur. Radiol. May 21 [Epub ahead of print].
Skakun NP, Tabachuk OE 1992 The comparative action of isoniazid, rifampicin and ethambutol on liver function. Eksp. Klin. Farmakol. 55: 45-47.
Snook JA, Chapman RW, Fleming K, Jewell DP 1989 Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin. Exp. Immunol. 76: 30-33. *
Sohda T, Shiga H, Nakane H, Nishizawa S, Yoshikane M, Anan A, Suzuki N, Irie M, Iwata K, Watanabe H, Sakisaka S 2005 Rapid-onset primary biliary cirrhosis resembling drug-induced liver injury. Intern. Med. 44: 1051-1054. *
Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF 1989 Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 96: 479-486.
Song XM, Li JG, Wang YL, Hu ZF, Zhou Q, Du ZH, Jia BH 2008 The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats. Shock Apr 3 [Epub ahead of print].
Sorbi D, Boynton J, Lindor KD 1999 The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am. J. Gastroenterol. 94: 1018-1022. *
Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M 1999 Hepatotoxicity by amoxicillin/clavulanic acid: case report. Rev. Med. Chil. 127: 1487-1491.
Steele IL, Levy C, Lindor KD 2007 Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20.
Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L 1994 Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J. Hepatol. 20: 57-64.
Sugawara Y, Makuuchi M, Takayama T, Imamura H, Kaneko J, Ohkubo T 2002 Safe donor hepatectomy for living related liver transplantation. Liver Transpl. 8: 58-62. *
Suzuki A, Lymp J, Donlinger J, Mendes F, Angulo P, Lindor K 2007 Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 5: 259-264.
Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K 2006 Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 26: 1209-1216. *
Svenberg T, Hammarstrom S, Andersson G, Johansson C, Samuelson K, Wahren B 1981 Serum level of biliary glycoprotein I, a determinant of cholestasis, of similar use as gamma-glutamyltranspeptidase. Scand. J. Gastroenterol. 16: 817-824.
T Hart NA, Van der Plaats A, Moers C, Leuvenink HG, Wiersema-Buist J, Verkerke GJ, Rakhorst G, Ploeg RJ 2006 Development of the isolated dual perfused rat liver model as an improved reperfusion model for transplantation research. Int. J. Artif. Organs 29: 219-227.
Taguchi M, Aridome G, Abe S, Kume K, Tashiro M, Yamamoto M, Kihara Y, Nakamura H, Otsuki M 2005 Autoimmune pancreatitis with IgG4-positive plasma cell infiltration in salivary glands and biliary tract. World J. Gastroenterol. 11: 5577-5581. *
Tahan G, Tarcin O, Tahan V, Eren F, Gedik N, Sahan E, Biberoglu N, Guzel S, Bozbas A, Tozun N, Yucel O 2007 The effects of N-acetylcysteine on bile duct ligation-induced liver fibrosis in rats. Dig. Dis. Sci. 52: 3348-3354. *
Taieb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, Vasseur S 2005 Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. Hepatology 42: 176-182. *
Tameda M, Shiraki K, Ooi K, Takase K, Kosaka Y, Nobori T, Tameda Y 2005 Aspartate aminotransferase-immunoglobulin complexes in patients with chronic liver disease. World J. Gastroenterol. 11: 1529-1531. *
Tanaka H, Tujioka H, Ueda H, Hamagami H, Kida Y, Ichinose M 2005 Autoimmune hepatitis triggered by acute hepatitis A. World J. Gastroenterol. 11: 6069-6071. *
Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y, Mamada Y, Yoshida H, Tajiri T 2008 Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J. Nippon Med. Sch. 75: 187-191. *
Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK 2005 Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol. Res. 31: 132-135.
Textor HJ, Flacke S, Pauleit D, Keller E, Neubrand M, Terjung B, Gieseke J, Scheurlen C, Sauerbruch T, Schild HH 2002 Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 34: 984-990.
Thirunavukkarasu C, Yang Y, Subbotin VM, Harvey SA, Fung J, Gandhi CR 2004 Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. Gut 53: 1010-1019. *
Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B 2008 PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol. Appl. Pharmacol. 231: 1-9. *
Tomkiewicz C, Muzeau F, Edgar AD, Barouki R, Aggerbeck M 2004 Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates. Biochem. Pharmacol. 67: 213-225. *
Tommasi AM, Fabris P, Carderi I, Baragiotta A, Baldo V, Venturi C, Giordani MT, Tositti G, Floreani A 2006 Lack of higher frequency of the chemokine receptor 5-Delta32/Delta32 genotype in hepatitis C. J. Clin. Gastroenterol. 40: 440-443.
Trauner M 2004 The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope? Hepatology 40: 260-263. *
Triester SL, Douglas DD 2005 Development of macro-aspartate aminotransferase in a patient undergoing specific allergen injection immunotherapy. Am. J. Gastroenterol. 100: 243-245. *
Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I 2001 Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. 7: 343-351. *
Tsuji H, Murai K, Akagi K, Fujishima M 1992 Familial primary biliary cirrhosis associated with impaired concanavalin A-induced lymphocyte transformation in relatives. Two family studies. Dig. Dis. Sci. 37: 353-360.
Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OF 1994 A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 9: 162-168.
Ulukaya S, Arikan C, Aydogdu S, Ayanoglu HO, Tokat Y 2003 Immediate tracheal extubation of pediatric liver transplant recipients in the operating room. Pediatr. Transplant. 7: 381-384.
Umemura T, Ota M, Yoshizawa K, Katsuyama Y, Ichijo T, Tanaka E, Kiyosawa K 2008 Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatol. Res. 38: 689-695. *
Utsunomiya T, Okamoto M, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Aishima S, Yoshikawa Y, Hanai T, Inoue H, Barnard GF, Mori M 2007 A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J. Gastroenterol. 13: 383-390. *
Valente AI, Almeida A, Gouveia A, Serejo F, Ramalho F, Baptista A, Saragoca A, Moura MC 1996 Prevalence of chronic hepatic disease in Portugal. Apropos of a review carried out in a hepatology unit. Acta Med. Port. 9: 197-202.
Valentine BA, Lohr CV 2007 Myonecrosis in three horses with colic: evidence for endotoxic injury. Vet. Rec. 161: 786-789.
Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA 2003 First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharmacol. Ther. 41: 441-449.
van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP 1997 Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand. J. Gastroenterol. 32: 369-373.
van Hoek B 1996 The spectrum of liver disease in systemic lupus erythematosus. Neth. J. Med. 48: 244-253.
Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR 1998 A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment. Pharmacol. Ther. 12: 965-971. *
van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW 1999 Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J. Hepatol. 31: 256-262. *
van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR 2000 Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am. J. Gastroenterol. 95: 2015-2022. *
van Hoogstraten HJ, Wolfhagen FH, verg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, et al 1998 Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J. Hepatol. 29: 417-423. *
van Runnard Heimel PJ, Kavelaars A, Heijnen CJ, Peters WH, Huisjes AJ, Franx A, Bruinse HW 2008 HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. Hypertens. Pregnancy 27: 253-265.
Venos ES, Knodel MH, Radford CL, Berger BJ 2004 Branched-chain amino acid aminotransferase and methionine formation in Mycobacterium tuberculosis. BMC Microbiol. 4: 39. *
Villanueva JA, Halsted CH 2004 Hepatic transmethylation reactions in micropigs with alcoholic liver disease. Hepatology 39: 1303-1310. *
Visalli T, Turkall R, Abdel-Rahman MS 2004 Cocaine hepatotoxicity and its potentiation by lipopolysaccharide: treatment and gender effects. Int. J. Toxicol. 23: 163-170. *
Visalli T, Turkall R, Abdel-Rahman MS 2005 Influence of gender on cocaine hepatotoxicity in CF-1 mice. Int. J. Toxicol. 24: 43-50.
Vleggaar FP, Monkelbaan JF, van Erpecum KJ 2008 Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur. J. Gastroenterol. Hepatol. 20: 688-692. *
Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ 2001 No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur. J. Gastroenterol. Hepatol. 13: 171-175.
Voigt MD, Workman B, Lombard C, Kirsch RE 1997 Halothane hepatitis in a South African population - frequency and the influence of gender and ethnicity. S. Afr. Med. J. 87: 882-885.
Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W 2008 Hepatoprotective effect of Hypericum japonicum extract and its fractions. J. Ethnopharmacol. 116: 1-6. *
Wang ZJ, Liu Q, Li PP, Zou CH, Shen ZF 2008 Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Eur. J. Pharmacol. 580: 277-283. *
Watanabe Y, Mori S, Fujiyama S, Sato T, Mori M 1995 Clinical evaluation of serum ornithine carbamoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 48: 18-26.
Wewer V, Gluud C, Schlichting P, Burcharth F, Binder V 1991 Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand. J. Gastroenterol. 26: 97-102.
Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG 2002 Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin. Chem. 48: 1426-1431. *
Wolfhagen FH, van Buuren HR, Schalm SW 1994 Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. Neth. J. Med. 44: 84-90.
Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJ, Hop WC, van der Hoek EW, Kerbert MJ, van Lijf HH, den Ouden JW, Smit AM, de Vries RA, van Zanten RA, Schalm SW 1998 Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J. Hepatol. 29: 736-742. *
Wood JR, Czaja AJ, Taswell HF, Ludwig J, Rakela J, Chase R 1987 Hepatitis B virus deoxyribonucleic acid in serum during hepatitis B e antigen clearance in corticosteroid-treated severe chronic active hepatitis B. Gastroenterology 93: 1225-1230.
Wu CH, Xu XY, Lu HY, Yu YY, Wang GQ 2004 Clinical and pathological analysis of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Beijing Da Xue Xue Bao 36: 609-611.
Wu CH, Xu XY, Tian GS, Yu YY 2006 Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus. Zhonghua Yi Xue Za Zhi 86: 390-393.
Wu J, Liu J, Waalkes MP, Cheng ML, Li L, Li CX, Yang Q 2008 High dietary fat exacerbates arsenic-induced liver fibrosis in mice. Exp. Biol. Med. (Maywood) 233: 377-384.
Wu J, Wang C, Liu Q, Yang T, Zhang Q, Peng J, Gao Y, Sun H, Kaku T, Liu K 2008 Protective effect of JBP485 on concanavalin A-induced hepatocyte toxicity in primary cultured rat hepatocytes. Eur. J. Pharmacol. 589: 299-305.
Wu PA, Kerner JA, Berquist WE 2006 Parenteral nutrition-associated cholestasis related to parental care. Nutr. Clin. Pract. 21: 291-295. *
Wu YL, Piao DM, Han XH, Nan JX 2008 Protective effects of salidroside against acetaminophen-induced toxicity in mice. Biol. Pharm. Bull. 31: 1523-1529. *
Xia F, Wang S, Ma K, Feng X, Su Y, Dong J 2008 The use of saline-linked radiofrequency dissecting sealer for liver transection in patients with cirrhosis. J. Surg. Res. Feb 1 [Epub ahead of print].
Yagi S, Iida T, Taniguchi K, Hori T, Hamada T, Fujii K, Mizuno S, Uemoto S 2005 Impact of portal venous pressure on regeneration and graft damage after living-donor liver